EcoR1 Capital IMNM Position
Active6-Fund ConvergenceEcoR1 Capital trimmed their position in Immunome Inc. (IMNM) in Q4 2025, holding $61.3M worth of shares across 2,855,590 shares.
The position was first reported in Q4 2023 and has been tracked across 9 quarterly 13F filings.
IMNM is a convergence signal: 6 specialist biotech funds hold this stock, suggesting high institutional conviction.
Short interest stands at 16.3% of float with 17.4 days to cover, indicating significant bearish positioning against EcoR1's long thesis.
1 insider purchase totaling $501K has been filed in the last 90 days, providing an additional conviction signal.
About Immunome Inc.
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
Full company profile →Short Interest
16.3%
17.4 days to cover
Insider Buys (90d)
1
$501K total
EcoR1 Capital IMNM Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q4 2025 | Decreased | 2,855,590 | -1,223,825 | $61.3M |
| Q3 2025 | Held | 4,079,415 | — | $47.8M |
| Q2 2025 | Held | 4,079,415 | — | $37.9M |
| Q1 2025 | Increased | 4,079,415 | +200,000 | $27.5M |
| Q4 2024 | Held | 3,879,415 | — | $41.2M |
| Q3 2024 | Held | 3,879,415 | — | $56.7M |
| Q2 2024 | Held | 3,879,415 | — | $46.9M |
| Q1 2024 | Held | 3,879,415 | — | $95.7M |
| Q4 2023 | New | 3,879,415 | +3,879,415 | $41.5M |
Frequently Asked Questions
Does EcoR1 Capital own IMNM?
Yes. As of Q4 2025, EcoR1 Capital holds 2,855,590 shares of Immunome Inc. (IMNM) valued at $61.3M. This data comes from their SEC 13F filing.
How many hedge funds own IMNM?
6 specialist biotech hedge funds currently hold IMNM, including Redmile Group, Driehaus Capital, Tang Capital Management and 2 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did EcoR1 Capital first buy IMNM?
EcoR1 Capital's position in IMNM was first reported in Q4 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is EcoR1 Capital's IMNM position increasing or decreasing?
EcoR1 Capital trimmed their IMNM position in the most recent quarter, reducing by 1,223,825 shares.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
IMNMCompany Page →
All fund holders, insider trades, catalysts, and cash runway
EcoR1 CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →